small molecule

IMBRUVICA

IBRUTINIB

Loss of exclusivityJune 2039latest FDA-listed patent expiry
CompanyPharmacyclics →See this company's full patent-cliff portfolio

Drug detail

Brand nameIMBRUVICA
Active ingredientIBRUTINIB
Strength70MG/ML
Dosage formSUSPENSION
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2022
Marketing statusRX

Listed patents

PatentExpiresType
12201690June 2039product
12364698April 2036product
9795604*PEDApril 2035—
10695350October 2034use U-2970
10463668October 2034use U-2970
9795604October 2034use U-2970
9296753*PEDApril 2034—
9725455*PEDDecember 2033—
10961251*PEDDecember 2033—
10125140*PEDDecember 2033—
10106548*PEDDecember 2033—
9296753October 2033substance
9725455June 2033substance
10106548June 2033substance, product
10125140June 2033substance, product
10961251June 2033product
10478439*PEDDecember 2031—
10016435June 2031use U-3845
10478439June 2031use U-3845
8999999June 2031use U-3844
9125889June 2031use U-3845
9801881June 2031use U-3847
9801883June 2031use U-3844
10004746June 2031use U-3847
10751342June 2031use U-3842
11672803June 2031use U-3843
8008309*PEDMay 2028—
8008309November 2027substance, product
9181257*PEDJune 2027—
8754091*PEDJune 2027—
8735403*PEDJune 2027—
8497277*PEDJune 2027—
7514444*PEDJune 2027—
8697711*PEDJune 2027—
8957079*PEDJune 2027—
8563563April 2027use U-3845
8735403December 2026substance, product
8754091December 2026product
7514444December 2026substance, product
9181257December 2026substance
8697711December 2026substance, product
8957079December 2026substance, product
8497277December 2026use U-2970
8476284December 2026use U-3845
8952015December 2026use U-3845
8703780December 2026use U-3842

Regulatory exclusivity

CodeExpires
PEDFebruary 2030
ODE-405August 2029
PEDFebruary 2026
NPAugust 2025

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.